

YIA applicant

IN VIVO TRACKING OF HUMAN NEURAL STEM CELLS IN THE MOUSE BRAIN WITH ¹⁹F MRIP. Böhm-Sturm¹, L. Mengler¹, S. Wecker², M. Hoehn¹, T. Kallur¹¹Max-Planck-Institute for Neurological Research, Cologne, Germany ²Medres-medical research GmbH, Cologne, Germany

(philipp.boehm-sturm@nf.mpg.de)

Introduction: MRI is a promising tool for monitoring stem cell based therapy. Conventionally, cells are loaded *in vitro* with iron oxide particles, which appear hypointense on ¹H MR images. However, the cell signal is not specific due to ambiguous background and not quantitative. An emerging field to overcome these drawbacks is ¹⁹F MRI of cells labeled with perfluorocarbon (PFC) emulsions [1]. Fluorine is virtually absent in the body, i.e. only labeled cells generate contrast, and quantification is possible as the signal is proportional to the concentration of ¹⁹F. Here it is shown, for the first time, that human neural stem cells (hNSCs), which have shown high therapeutic potential for brain pathology [2], can be labeled with PFCs, detected and quantified *in vitro* and after brain implantation.

Methods: hNSCs were incubated with a PFC emulsion (CELSENSE 1000, Celsense, USA), viability was assessed with trypan blue exclusion, and immunocytochemistry was carried out to evaluate the influence of the label on cell phenotypes. For *in vitro* MRI, hNSCs were suspended in gelatin at varying densities. For *in vivo* experiments, 150.000-300.000 labeled hNSCs or non-labeled controls were implanted into the striatum of mice (n=4). Animals were scanned with ¹H MRI and ¹⁹F MRI (total time < 1.5 h, 400x400x1000 μm^3 ¹⁹F image resolution) on an 11.7 T scanner (Bruker BioSpec, Ettlingen, Germany) and transcardially perfused after the last MRI session.

Results: hNSCs were labeled most efficiently at a concentration of 80 μl emulsion/ml medium. The labeling led to a decrease of cell viability compared to controls directly after incubation (83 \pm 4 % vs. 93 \pm 7 % living cells, p<0.05), which re-normalized after 7 days in culture of the replated cells. We did not detect label-related changes in the numbers of Ki67, nestin, GFAP, or β III-tubulin+ cells during both, proliferation and differentiation. The dilution series indicated that 1.000 hNSCs needed to accumulate in one image voxel to generate significant signal to noise ratio (SNR) *in vitro*. We detected grafts *in vivo* with ¹⁹F MRI over several days but not the controls. From SNR analysis we estimate a detection limit of a few 10.000 cells/voxel. The location and density of human cells (hunu+) on histological sections correlated well with observations in the ¹⁹F MR images.

Conclusion: Our results show that hNSCs can be labeled with ¹⁹F with little effects on viability or proliferation and differentiation capacity. Our optimized settings allowed higher resolution and a lower detection limit than in other reports on MRI of ¹⁹F labeled cells. This proves for the first time that ¹⁹F MRI can be utilized for cell tracking in brain implantation studies, in which the graft may be initially small or diluted through cell migration induced by the damage.

Acknowledgements: We thank Dr. O'Hanlon for the generous supply of CELSENSE. This work was supported by grants from the EU FP6 program (StemStroke, LSHB-CT-2006-037526), FP7 program (ENCITE, 201842), and the German Federal Ministry of Education and Research (BMBF 0314104).

References: [1] Ahrens et al, Nat Biotech (2005), 23(8):983-987; [2] Darsalia et al, Eur J Neurosci (2006), 28(8):1630-1644